$13.72
2.31% today
NYSE, Feb 05, 04:16 pm CET
ISIN
US03969F1093
Symbol
RCUS

Arcus Biosciences Stock price

$13.41
-1.46 9.82% 1M
-0.37 2.69% 6M
-1.48 9.94% YTD
-1.81 11.89% 1Y
-15.99 54.39% 3Y
+3.40 33.97% 5Y
-3.59 21.12% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.21 1.59%
ISIN
US03969F1093
Symbol
RCUS
Sector
Industry

Key metrics

Market capitalization $1.23b
Enterprise Value $196.17m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.75
P/S ratio (TTM) P/S ratio 4.67
P/B ratio (TTM) P/B ratio 2.17
Revenue growth (TTM) Revenue growth 119.80%
Revenue (TTM) Revenue $263.00m
EBIT (operating result TTM) EBIT $-298.00m
Free Cash Flow (TTM) Free Cash Flow $-169.00m
Cash position $1.09b
EPS (TTM) EPS $-3.15
P/E forward negative
P/S forward 4.69
EV/Sales forward 0.75
Short interest 18.59%
Show more

Is Arcus Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Arcus Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Arcus Biosciences forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Arcus Biosciences forecast:

Buy
73%
Hold
27%

Financial data from Arcus Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
263 263
120% 120%
100%
- Direct Costs 12 12
17% 17%
5%
251 251
139% 139%
95%
- Selling and Administrative Expenses 97 97
11% 11%
37%
- Research and Development Expense 440 440
34% 34%
167%
-286 -286
7% 7%
-109%
- Depreciation and Amortization 12 12
17% 17%
5%
EBIT (Operating Income) EBIT -298 -298
8% 8%
-113%
Net Profit -270 -270
8% 8%
-103%

In millions USD.

Don't miss a Thing! We will send you all news about Arcus Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcus Biosciences Stock News

Neutral
Business Wire
12 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company's commo...
Neutral
Business Wire
15 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who ...
Positive
Seeking Alpha
22 days ago
Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will report important updates in 2025. One of Domvanalimab's combinations showed that it can help overall survival by a whopping 36% in NSCLC. It also had lower discontinuation rates than chemotherapy.
More Arcus Biosciences News

Company Profile

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Head office United States
CEO Terry Rosen
Employees 577
Founded 2015
Website www.arcusbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today